Takeaways Bepirovirsen’s Canada filing signals a coming shift in the hepatitis B market from lifelong viral suppression to time‑limited “functional cure” regimens, which could reshape how p...
Home / FDA Breakthrough Therapy Designation
Browsing Tag: FDA Breakthrough Therapy Designation
Social Icons
Featured Posts
1
AbbVie’s Boey Approved in Canada for Glabellar Lines
June 24, 20262
Roche’s Itovebi Moves Closer to Public Access in Canada
June 24, 20263
